Calyxt, Inc. has announced two new hires—Suellen Boot will assume the position of business development director, while Elizabeth Teigland will take on the role of manufacturing director.
Boot brings more than 20 years of business development expertise to Calyxt, where she will lead partnerships, deal structuring, valuation modeling, transaction execution and alliance management for the company’s key target markets.
Teigland brings over 15 years of chemistry and purification expertise to Calyxt. She will be responsible for leading and managing the optimization of the company’s BioFactory Production System and play a significant role in helping to facilitate pilot to commercial-scale production of the of customer demand-driven compounds.
Boot most recently served as managing director, Natural Innovation & Operation at Green Line. Prior to that, she served as vice president of sales and marketing at Bio Component Research, and Global Manager, Technical Marketing at Lonza Consumer Care and at Arch Personal Care Products. Previously, she held several marketing manager and global product roles at Croda Inc., GE Advanced Materials, and Brooks Industries, Inc. Boot holds a Bachelor of Science in biochemistry from St. Andrews Presbyterian College.
Teigland joins Calyxt from Agropour Ingredients, where she served as director of Protein Research and led a cross-functional, global team with ingredient and reliable method development. Prior to that, she served as research scientist at Saputo Dairy Foods USA, and as field application specialist at m2p-labs GmbH. Previously, Teigland held various biotechnology and chemistry roles at Cargill, Inc. She holds a Bachelor of Science in biochemistry and chemistry from University of Iowa and a Master of Science in chemistry and microbiology from University of Oregon.
Michael. A Carr, president and chief executive officer at Calyxt, said, “I am pleased to welcome Suellen and Elizabeth to Calyxt. Their arrivals are critical for advancing two of our near-term revenue streams: business development and BioFactory commercialization. Each of these talented individuals bring unique skills that equip our company for increased growth and momentum.”
Carr continued, “Suellen’s experience is well aligned with our strategy to deliver plant-based synthetic biotechnology solutions to target customers in the identified key end markets of cosmeceuticals, nutraceuticals, and pharmaceuticals. Furthermore, Elizabeth’s experience in portfolio management for innovation, commercialization, and product development will bolster our plant chemistry manufacturing and production capabilities. Both hires are important steps in executing on our business plan and key milestone achievements.”